Archives
- 2026-09
- 2026-08
- 2026-07
- 2026-06
- 2026-05
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
-
Bismuth Subsalicylate in Cell Assay Workflows
2026-09-27
This practical guide explains how to evaluate Bismuth Subsalicylate (SKU A8382) in viability, proliferation, and apoptosis workflows without mistaking compound-handling effects for biological results. It combines product specifications with literature-supported annexin V principles and highlights controls, formulation limits, and vendor-selection considerations.
-
Anlotinib Hydrochloride: Reading Angiogenesis Assays
2026-09-26
Anlotinib hydrochloride is a multi-target tyrosine kinase inhibitor for studying angiogenic signaling. This guide focuses on a practical question often missed in mechanism summaries: how to distinguish receptor-pathway suppression from general cell stress when interpreting endothelial assays.
-
Anlotinib Hydrochloride in Angiogenesis Assays
2026-09-25
Use Anlotinib hydrochloride to connect VEGFR2, PDGFRβ, and FGFR1 inhibition with practical endothelial migration, tube-formation, and ERK readouts. A rare-tumor case report adds translational context, while the workflows below keep cell-based findings distinct from clinical evidence.
-
Doxorubicin Hydrochloride: Applied Research Workflows
2026-09-25
Turn Adriamycin HCl into a reproducible tool for cancer-cell response studies and cardiac injury models, with practical guidance on dose finding, assay selection, and troubleshooting. A recent ATF4–H₂S study adds a mechanistic framework for testing oxidative stress and cardioprotection alongside doxorubicin exposure.
-
Ruxolitinib Triggers ATC Cell Death Through DRP1
2026-09-24
The study links JAK1/2–STAT3 inhibition by ruxolitinib to reduced DRP1 transcription, impaired mitochondrial fission, and caspase-dependent apoptosis and GSDME-mediated pyroptosis in anaplastic thyroid carcinoma models. Its mechanistic findings identify DRP1 as a connection between STAT3 signaling and mitochondrial dynamics, while supporting further preclinical investigation rather than establishing clinical efficacy in patients.
-
Fosinopril Sodium: From ACE Mechanism to Translation
2026-09-24
A translational guide to using Fosinopril sodium in hypertension and cardiovascular research, connecting ACE inhibition and prodrug pharmacology with experimental design, evidence boundaries, and clinical context.
-
Anlotinib Hydrochloride: Translating Angiogenesis Biology
2026-09-24
Anlotinib hydrochloride offers translational researchers a way to interrogate how VEGFR2, PDGFRβ, and FGFR1 converge on ERK signaling and angiogenic behavior. This article connects target-level potency with functional assay design, considers what a reported desmoplastic small round cell tumor case can—and cannot—tell us, and outlines practical steps for building more informative cancer research models.
-
Moesin as a Biomarker of Endothelial Injury in Sepsis
2026-09-23
The reference study identifies circulating moesin as a candidate marker of endothelial injury and sepsis severity, linking higher levels with SOFA scores, procalcitonin, pulmonary edema, and lung damage. Its combination of patient observations, mouse models, and endothelial-cell experiments also suggests that moesin contributes functionally through ROCK1/MLC and NF-κB signaling rather than serving only as a passive indicator.
-
Apigenin Workflows for HDAC and Neuroprotection
2026-09-22
Apigenin supports two complementary bench strategies: malignant mesothelioma cell growth inhibition through HDAC-linked apoptosis, and neuroprotection studies integrating oxidative stress, mitochondrial injury, and inflammation. This practical guide connects dose selection, assay controls, workflow design, and troubleshooting without overstating preclinical findings.
-
Aβ25-35: A Translational Lens on AD Neurotoxicity
2026-09-22
Amyloid Beta-peptide (25-35) (human) is more than a cytotoxicity reagent: it is a reductionist tool for connecting mitochondrial stress, oxidative injury, amyloid aggregation, microglial state, and tau-related signaling. This thought-leadership guide shows how to deploy Aβ25-35 strategically while interpreting its findings against the more complex FLOT1–FOSL2–EphA2 inflammatory axis described in Alzheimer’s disease models.
-
AT-406 (SM-406): From IAP Binding to Death-Mode Data
2026-09-21
AT-406 (SM-406) is an orally bioavailable IAP antagonist whose value extends beyond apoptosis induction. This guide connects target engagement, death-mode profiling, and assay design to clarify how cancer researchers can interpret AT-406 responses across ovarian and triple-negative breast cancer models.
-
Tamsulosin: From α1A Pharmacology to Assay Design
2026-09-21
Tamsulosin is more than a urinary-flow modulator: it is a useful pharmacological probe for connecting α1A receptor signaling with tissue-level assay endpoints. This article integrates C6445 product data with a critical analysis of testosterone-bounce methodology in prostate cancer research.
-
USP42 Drives Breast Cancer via JNK/p38 Apoptosis
2026-09-20
The reference study identifies USP42 as a pro-tumorigenic regulator in breast cancer and links its activity to suppression of JNK/p38-associated apoptosis. By combining USP42 knockdown, pathway inhibition, cellular assays, and xenograft validation, the work provides a mechanistic basis for investigating USP42 as a preclinical therapeutic target.
-
Microplastics, Vitamin B6, and PCOS in Mice
2026-09-19
The reference study identifies a gut microbiota–vitamin B6–ovary axis through which polystyrene microplastics worsen DHEA-induced polycystic ovary syndrome in mice. Its vitamin B6 rescue experiments connect microbial disruption with ovarian inflammation, oxidative stress, endocrine abnormalities, and impaired reproductive function.
-
ECM Internalisation, p38β, and Cancer Cell Invasion
2026-09-19
Martinez and colleagues developed a live-cell, high-content assay that revealed extracellular matrix internalisation as a regulated process linked to invasive carcinoma migration. Their data identify an α2β1 integrin–MAP3K1–p38β–NHE1 axis and show that ECM trafficking supports migration and invasion in both two-dimensional and three-dimensional models.